Cyclacel Pharmaceuticals

Ver el organigrama con sus 8 ejecutivos principales

Biografías más buscadas en Cyclacel Pharmaceuticals

• Spiro Rombotis, President, Chief Executive Officer, Director
• Samuel Barker, Director
• Christopher Henney, Chairman of the Board

Recientes movimientos de ejecutivos en Cyclacel Pharmaceuticals

• Brian Schwartz que ha sido Director, ha ascendido a Chief Medical Officer and Director  (noticia publicada el 30 de enero de 2024).
• Mark Kirschbaum, Senior Vice President and Chief Medical Officer, ha dejado la empresa  (noticia publicada el 30 de enero de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals tiene 1.869 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacia

• AstraZeneca has announced the acquisition of Fusion Pharma  (publicado el 23 de marzo de 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (publicado el 19 de marzo de 2024).
• Frontier Medicines acaba de anunciar una recaudación de fondos de 80 millones de dólares. (publicado el 27 de febrero de 2024).

Otros contactos sugeridos en el sector Farmacia

• Jean-Frédéric Paulsen - Executive Chairman of the Board en Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director en Dirk Rossmann
• Thierry Abribat - Chief Executive Officer en Amolyt Pharma

Saber más sobre el sector Farmacia >

Últimos comunicados de prensa de Cyclacel Pharmaceuticals

• Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results | Cyclacel Pharmaceuticals, Inc.
• RSS News Feeds | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020 | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
• Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
• CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING | Cyclacel Pharmaceuticals, Inc.
• View more press releases Close

Redes sociales sobre Cyclacel Pharmaceuticals

• Cyclacel Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Cyclacel Pharmaceuticals en LinkedIn, Twitter y YouTube

Contactar a través de e-mail con sus ejecutivos Spiro Rombotis

Llame a Cyclacel Pharmaceuticals al +1 908...

Ver el organigrama

Register to receive your alert

Señalar un error